Planned 2022 Clinical Trial Will Test LP352 in Reducing Seizures

Planned 2022 Clinical Trial Will Test LP352 in Reducing Seizures

306665

Planned 2022 Clinical Trial Will Test LP352 in Reducing Seizures

Longboard Pharmaceuticals is planning to launch a Phase 1b/2a clinical trial early next year that will evaluate the company’s investigational therapy LP352 in adults with Dravet syndrome and other types of developmental and epileptic encephalopathies (DEEs). The trial will test the therapy’s effectiveness in lessening seizures in patients with Dravet and other types of epilepsy characterized by episodes of prolonged seizures. “We believe LP352 has the potential to reduce seizures in a broad range of…

You must be logged in to read/download the full post.